JP2002145764A - Composition for pharyngeal mucous membrane - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a composition for pharyngeal mucous membrane considerably reducing an uncomfortable feeling at the pharynx and masked in bitterness. SOLUTION: This composition for pharyngeal mucous membrane considerably reduced in an uncomfortable taste such as an astringent taste by polyphenol is obtained by formulating the polyphenol, ethanol and concentrated glycerin.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

TECHNICAL FIELD The present invention relates to a composition for pharyngeal mucosa used when the pharynx is uncomfortable.

[0002]

2. Description of the Related Art A typical example of a person who feels discomfort in the pharynx is a viral illness such as a cold syndrome which is a disease accompanied by various systemic symptoms such as malaise as well as local inflammatory symptoms mainly in the upper respiratory tract. In case of infection with respiratory infection. Pharyngeal hyperemia or swelling, which is an inflammatory symptom of the upper respiratory tract, is a symptom that frequently occurs when a person has the cold syndrome, and removal / remission of discomfort such as pharyngeal pain, which is a subjective symptom of this symptom. Plays a central role in symptomatic treatment.

[0003] In addition, it is known that irritation of the pharyngeal mucosa due to allergy or air pollution damages the mucosal surface, and consequent redness and swelling of the pharynx can be perceived as uncomfortable. Therapy is the main.

[0004] In symptomatic treatment, generally, a troche, a drop, a lick, a gargle, a stream, a spray, or the like containing a bactericidal disinfectant, an anti-inflammatory enzyme, a local anesthetic, a Chinese medicine or iodine as an active ingredient is used. It has been used in dosage forms.

[0005] In addition, swelling and damage of the pharyngeal mucosa create new viral infections, secondary infections of bacteria, exposure to various allergens and air pollutants, and increase the severity of the discomfort, prolong the discomfort, and cause systemic symptoms. Take risks that can easily lead to expansion.

[0006] It is known that a large amount of polyphenol is contained in tea, and it is known that the polyphenol in tea protects against infection of various viruses and bacteria (Patent Registration No. 2724771, JP-A-3-106820, JP-A-3-246227).

[0007] Polyphenols can be broadly classified into hydrolyzable tannins and condensed tannins. In particular, hydrolyzable tannins have an unpleasant taste such as a very strong astringency. In addition, polyphenols have low stability and are easily decomposed particularly in liquid preparations. Therefore, development of a drug excellent in efficacy, duration, convenience and feeling of use is desired.

[0008]

SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for pharyngeal mucosa which is excellent in efficacy, duration, convenience and usability in order to remove or reduce discomfort in the pharynx. is there.

[0009]

Means for Solving the Problems The present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, by blending polyphenol as an active ingredient and ethanol and concentrated glycerin as bases, the reduction of polyphenols has been achieved. It has been found that a composition for pharyngeal mucosa that can alleviate unpleasant taste such as taste and can significantly improve the feeling of use can be obtained. Further, they have found that a composition for pharyngeal mucosa in which a polyphenol is stably present for a long time can be obtained by blending an inorganic acid or a buffer solution comprising an inorganic acid, thereby completing the present invention.

[0010]

BEST MODE FOR CARRYING OUT THE INVENTION The composition for pharyngeal mucosa according to the present invention comprises polyphenol as an active ingredient, ethanol and concentrated glycerin as bases, and the blending ratio of ethanol and concentrated glycerin is 1: 2.3 to 9 by weight. It is preferable that 0.2 to 5% of polyphenol is blended with respect to the total amount of the composition. The weight ratio of the most preferred formulation of polyphenol, ethanol and concentrated glycerin is 2:20:80. Further, when the pH is adjusted to 1 to 3 by adding an appropriate amount of an inorganic acid or a buffer solution comprising an inorganic acid to the pharyngeal mucosa composition of the present invention, the polyphenol can be stably present for a long time. If the amount of the polyphenol is less than 0.2% of the total amount of the composition, the effect of preventing virus infection cannot be expected, and 5
%, The unpleasant taste cannot be alleviated.

In the present invention, polyphenols include:
Hydrolysable tannins are preferred, and the hydrolysable tannins include tannic acid, gallic acid, gallic acid derivatives, galloyl gallic acid, luteonic acid, ellagic acid or their analogous substances and salts thereof, and most preferably. Is tannic acid.

The inorganic acid or the buffer comprising an inorganic acid is not particularly limited as long as it is an inorganic acid or a buffer comprising an inorganic acid which can be administered to a human. For example, as the inorganic acid, hydrochloric acid,
Phosphoric acid, boric acid or hydrobromic acid. Also,
Examples of the buffer composed of an inorganic acid include a hydrochloric acid-potassium chloride buffer, a hydrochloric acid-glycine buffer, and a phosphate-glycine buffer. The buffer consisting of an inorganic acid or inorganic is preferably hydrochloric acid, phosphoric acid, boric acid, hydrobromic acid or hydrochloric acid-potassium chloride buffer hydrochloric acid. Considering the feeling in use, hydrochloric acid is most preferred.

The composition for pharyngeal mucosa of the present invention is used for cold medicine, antitussive expectorant, rhinitis medicine, pharyngeal medicine, cold prevention medicine, oral disinfectant, oral antiphlogistic, bad breath remover, etc. It can be used in a wide variety of forms such as quasi-drugs and medical devices as needed.

The composition for pharyngeal mucosa of the present invention may further comprise, if necessary, an antiallergic drug, an antipyretic analgesic, an anti-inflammatory enzyme, a bronchodilator, an antitussive, an expectorant, a sympathomimetic, an anticholinergic. Ingredients such as caffeine, vitamins, other crude drugs, and fragrances can be appropriately blended. These ingredients can be used alone or in combination with each other.Normally, the standards for antitussive expectorants and gargles for over-the-counter drugs listed in the Pharmaceutical Manufacturing Guidelines (1995 Pharmaceutical Times Co., Ltd.), It is blended according to the description of the dental oral preparation.

The composition for pharyngeal mucosa of the present invention can be prepared by a conventional method. Excipients, lubricants, disintegrating agents and the like can be used in the case of solid preparations, and surfactants, solubilizing agents, buffers and the like can be used in the case of liquid preparations as needed. In addition, other preservatives, flavors, pigments, sweeteners / flavors, fresheners, coloring agents, and the like can be used.

[0016]

According to the present invention, an unpleasant taste such as astringent taste of polyphenol can be remarkably improved by blending polyphenol, ethanol and concentrated glycerin having an unpleasant taste as an active ingredient, and discomfort in the pharynx can be reduced. Further, by adding an inorganic acid or a buffer solution composed of an inorganic acid, a composition for pharyngeal mucosa in which the polyphenol is stably present in the solution for a long time can be obtained.

[0017]

The present invention will be described in more detail with reference to the following examples and test examples, but the present invention is not limited to the following examples.

Example 1 The following components and amounts were weighed and uniformly dissolved to obtain 1000 g of a drug for pharyngeal mucosa. Tannic acid 20.0 g Ethanol 194.0 g Concentrated glycerin 774.0 g l-menthol 12.0 g

Example 2 The following components and amounts were weighed and dissolved uniformly,
The mixture was adjusted to H2 to obtain 2000 g of Lugol's solution.

Tannic acid 26.0 g Iodine 10.0 g Potassium iodide 20.0 g Concentrated glycerin 1032.9 g Mint oil 0.4 g Ethanol 255.7 g Hydrochloric acid 655.0 g

Example 3 The following components and amounts were weighed and uniformly dissolved.
H1 to give 1000 g of nasal drops. Sodium gallate 20.0 g Benzethonium chloride 0.2 g JP glycerin 60.0 g Ethanol 7.0 g Hydrochloric acid 100.0 g Purified water qs

Test Example 1 Astringency masking test Test method Example 1 was used as a test drug, and a control drug having the following formulation was used as a stream agent. The oral cavity was washed by 48 healthy persons and used for 6 days a day for 3 days, and the impression of astringency of the test drug and the control drug was compared. In addition, impression is "5 points: feel very unbearable astringency""4 points: feel very astringent"
"3 points: Feel the astringency""2 points: Feel the mild astringency"
The evaluation was made on a six-point scale of "1 point: slightly felt astringency" and "0 point: no feeling of astringency", and the number and ratio of those who scored 2 or more points were reduced.

Control formulation (1000 g total) 80 g tannic acid Purified water

Results The results of the astringency masking test are shown below. In this determination, the test drug group of the present invention was superior to the control drug group, and it was shown that astringency was reduced.

Difference between control drug evaluation and test drug evaluation (control drug evaluation point-test drug evaluation point) Point difference Number of people 5 points 4 points 21 points 3 points 19 points 2 points 4 points 1 point 1 point 0 points 0 Person -1 point 1 person

Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI Theme coat II (reference) A61P 31/04 A61P 31/04 31/12 31/12 F term (reference) 4C076 AA12 BB21 CC31 DD22Z DD37A DD37E DD38A DD38E FF15 4C086 AA01 AA02 EA03 MA01 MA04 MA56 NA09 NA14 ZA59 4C206 AA01 AA02 DA19 KA01 MA01 MA04 MA37 MA76 NA09 NA13 ZA59

Claims (8)

[Claims] 1. A composition for the pharyngeal mucosa comprising a polyphenol, ethanol and concentrated glycerin. 2. The composition for pharyngeal mucosa according to claim 1, wherein the polyphenol is a hydrolyzable tannin. 3. The method according to claim 2, wherein the hydrolyzable tannin is one or more selected from tannic acid, gallic acid, gallic acid derivatives, galloyl gallic acid, luteonic acid, ellagic acid and salts thereof. Composition for pharyngeal mucosa 4. The composition for pharyngeal mucosa according to claim 1, wherein the weight ratio of ethanol and concentrated glycerin is 1: 2.3-9. 5. The composition for pharyngeal mucosa according to claim 1, wherein the polyphenol is incorporated in an amount of 0.2 to 5% based on the total amount of the composition for pharyngeal mucosa. 6. The composition for pharyngeal mucosa according to claim 1, further comprising an inorganic acid or a buffer solution comprising an inorganic acid. 7. The composition for pharyngeal mucosa according to claim 1, wherein the pH is in the range of 1 to 3. 8. The method according to claim 6, wherein the inorganic acid or the buffer comprising the inorganic acid is one or two selected from hydrochloric acid, phosphoric acid, boric acid, hydrobromic acid and hydrochloric acid-potassium chloride buffer. Composition for pharyngeal mucosa